A letter from Ameli (French Health Insurance)
27 October 2022, by Cancer RoseUpdated December 2022 Dear Sir or Madam, Your attending physician...
Screening: it is urgent to improve the information for women
DECEMBER 14, 2022, BY CANCER ROSE Recently, we relayed the EU Council’s new screening guidelines,...
Caution of the Council of European Union regarding screenings extension
By Cancer Rose, December 11, 2022 In September 2022, the European Commission issued recommendations for...
The short news of October 2022
Synthesis Dr C.Bour, October 20, 2022 1°-We start with an article in Medscape, written by...
The new INCa 2022 booklet on breast cancer screening
October the 20th In 2017, we conducted a critical review of the French National Cancer...
A new EU approach to cancer screening
September 22, 2022 – Abstract Dr. C.Bour https://ec.europa.eu/commission/presscorner/detail/fr/QANDA_22_5584 Within the framework of the European program...
Liquid biopsies, the Grail?
Synthesis Dr. C.Bour, September 15, 2022 Main article Article by Brenna Miller The Damocles syndrome...
The risks of screening: an elephant in the room
This article proposes a synthesis of two points of view of Dutch academics written for...
Potential benefits, as well as harms, from the COVID-19 disruption on cancer screening
May, 28th Online early publication https://doi.org/10.17061/phrp32122208https://www.phrp.com.au/wp-content/uploads/2022/04/PHRP32122208.pdf During the Covid pandemic, some scientists and journalists from various...